What is Sermorelin?
The short answer
Sermorelin is a lab-made copy of part of the hormone that tells the body to make growth hormone.
What it is
Stimulates the pituitary to release growth hormone.
What people look into
Muscle and exercise, aging, sleep
- 6 sources
- Status as of
- How we source
- Ellum doesn't sell peptides.
Get updates on Sermorelin
What it is
- Type
- GHRH analog (peptide)
- Also known as
- sermorelin acetate, geref, grf 1-29
- How it works
- Stimulates the pituitary to release growth hormone.
Regulatory status
FDA-approved, discontinued How we label status
As of October 4, 2026, no FDA-approved Sermorelin product for human use is sold in the US. FDA approved Geref for human use in 1990; it has been discontinued.
- Federal (FDA)
- Approved 1990 (Geref NDA019863/NDA020443), discontinued; Drugs@FDA: FR determination not withdrawn for safety or effectiveness
- 503A compounding
- No 503A category; 503B Category 1 as approved-drug component (as of March 21, 2025)
- WADA 2026
- S2.2.4
US enforcement actions
2 US enforcement actions since 2022.
Actions by US federal and state agencies whose documents name Sermorelin. Each row links to the government's own document.
Scroll sideways to see all columns.
US enforcement actions table
| Date | Agency | Action | Document |
|---|---|---|---|
| FDA | Warning letter | FDA document, warning letter, December 10, 2024, on fda.gov | |
| FDA | Warning letter | FDA document, warning letter, January 26, 2022, on fda.gov |
References
Sources as of October 4, 2026
- Drugs@FDA: www.accessdata.fda.gov/scripts/cder/daf/index.cfm (1 of 2)
- Drugs@FDA: www.accessdata.fda.gov/scripts/cder/daf/index.cfm (2 of 2)
- FDA: www.fda.gov/media/94164/download
- FDA warning letter, January 26, 2022
- FDA warning letter, December 10, 2024
- WADA: www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf